[Clinical studies on the question of toxicity of prolonged administration of cyclamate in patients with liver and kidney diseases].
D000328:Adult; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D001806:Blood Urea Nitrogen; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000503:physiopathology* / Q000652:urine; D007677:Kidney Function Tests; D007958:Leukocyte Count; D008107:Liver Diseases / Q000097:blood / Q000503:physiopathology* / Q000652:urine; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011507:Proteinuria; D013549:Sweetening Agents / Q000633:toxicity*; D014557:Urobilin / Q000652:urine
D001798:Blood Proteins; D010919:Placebos; D013549:Sweetening Agents; D014557:Urobilin; D002784:Cholesterol; D003404:Creatinine; D001219:Aspartate Aminotransferases; D001663:Bilirubin
Klinische Untersuchungen zur Frage der Toxizität langzeitiger Gaben von Cyclamat bei Patienten mit Leber- und Nierenkrankheiten.